- In recent weeks, AbbVie has secured multiple regulatory wins, including EU approval of AQUIPTA for acute migraine, expanded EU labeling for VENCLYXTO combinations in untreated CLL, and U.S. FDA approval of DECNUPAZ for BPDCN.
- These moves broaden AbbVie’s neurology and oncology reach into new patient groups, potentially deepening its portfolio beyond its core immunology blockbusters.
- We’ll now examine how EU approval of AQUIPTA for acute migraine shapes AbbVie’s existing investment narrative around portfolio diversification and growth.
Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
AbbVie Investment Narrative Recap
To own AbbVie, I think you need to believe its newer therapies and pipeline can more than offset patent and pricing pressure on its legacy blockbusters. The AQUIPTA EU migraine approval reinforces the diversification story into neurology, but does not materially change the near term focus on Humira erosion, pricing headwinds, and execution on Skyrizi and Rinvoq as key drivers and risks.
Among the recent announcements, the expanded EU label for VENCLYXTO combinations in first line CLL feels most connected to this story, because it underlines AbbVie’s push to deepen oncology beyond a few core assets. Together with AQUIPTA, it highlights how multiple, smaller approvals may collectively matter for offsetting concentration risk in immunology if they can scale into meaningful, recurring oncology and neuroscience revenue pools.
However, while diversification helps, investors should still be aware of the concentrated product risk if competitor breakthroughs emerge in...
Read the full narrative on AbbVie (it's free!)
AbbVie’s narrative projects $77.7 billion revenue and $22.4 billion earnings by 2029. This requires 8.3% yearly revenue growth and a roughly $18.2 billion earnings increase from $4.2 billion today.
Uncover how AbbVie's forecasts yield a $249.43 fair value, a 16% upside to its current price.
Exploring Other Perspectives
Three members of the Simply Wall St Community currently see AbbVie’s fair value between US$249 and US$416 per share, underlining how far apart individual views can be. Before weighing those against your own expectations, it is worth considering how heavily AbbVie still relies on a concentrated portfolio in immunology and neuroscience for its future earnings power.
Explore 3 other fair value estimates on AbbVie - why the stock might be worth as much as 93% more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your AbbVie research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
- Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.
Curious About Other Options?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com